Licensing status

Publication and contact information

Cardiovascular disease


MicroRNA-146a (miR-146a)

In vitro and mouse studies suggest inhibiting miR-146a could help treat peripartum cardiomyopathy (PPCM). In patients with PPCM and in mouse models for the indication, plasma or cardiac levels of miR-146a were higher than those in healthy postpartum controls. In the PPCM mouse models, a locked nucleic acid (LNA) anti-miR-146a increased cardiac function and capillary density and decreased cardiac fibrosis compared with a control oligonucleotide. Future studies could include testing the LNA anti-miR-146a in additional models for PPCM.

SciBX 6(18); doi:10.1038/scibx.2013.438
Published online May 9, 2013

Patent and licensing status unavailable

Halkein, J. et al. J. Clin. Invest.; published online April 24, 2013;
Contact: Ingrid Struman, University of Liege, Liege, Belgium